AHSA1 and AL amyloidosis: Understanding which moieties drive CRBN binding with Hsp90 and Aha1 could represent an attractive approach for the development of novel therapies for multiple myeloma or other conditions driven by membrane proteins (Heider et al., 2021; Eichner et al., 2016).